Dear Doctor Letter (Rote-Hand-Brief) on Levact® (bendamustine): increased mortality observed in recent clinical studies with bendamustine
2017.08.29
Active substance: bendamustine
The company Astellas is circulating information that an increased mortality was observed in recent clinical studies when bendamustine was used in non-approved combination treatments or outside the approved indications. Fatal toxicities were mainly due to (opportunistic) infections.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN